fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Vista Alert: Indaptus Therapeutics Offers Novel Immunotherapy Decoy20 Cancer Treatment Progress Update – $INDP $MRK $NVS $PFE $XBI

By John F. Heerdink, Jr.
Decoy20 represents a novel approach to cancer immunotherapy. Unlike current treatments that target specific immune pathways, Decoy20 aims to activate a broad antitumor response from both innate and adaptive immune systems. Composed of attenuated and killed non-pathogenic Gram-negative bacteria, Decoy20 acts as a “decoy” to trigger multiple immune receptors, including Toll-like receptors (TLRs), without excessive toxicity. Preliminary results from the ongoing Phase 1 trial show that Decoy20 induces rapid immune activation followed by quick clearance from the body, supporting the company’s “pulse-prime” hypothesis. The treatment has demonstrated manageable adverse events and consistent immune responses across different dose levels. Based on promising preclinical results, Indaptus plans to advance Decoy20 into combination studies with checkpoint inhibitors i.e. Merck’s (MRK) multi-billion dollar blockbuster cancer treatment drug Keytruda, that already treats 17 types of cancers, potentially offering a new treatment option for patients with advanced solid tumors who have limited alternatives.

Indaptus Therapeutics (NASDAQ: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced on September 5, 2024, encouraging safety data for its Decoy20 cancer treatment program. According to the company’s latest press release, the independent Safety Review Committee has approved continued dosing of patients at two different weekly doses, marking a significant milestone in the clinical trial’s progression. This progress sets the stage for potential combination therapy trials next year, as Indaptus aims to leverage Decoy20’s ability to activate multiple immune pathways for enhanced tumor regression.  

Confirming Encouraging Progress

 
Roger Waltzman, M.D., M.B.A. currently serves as our Chief Medical Officer.

Roger Waltzman, M.D., M.B.A., Chief Medical Officer Of Indaptus Therapeutics (NASDAQ: INDP)

“We continue to be encouraged by the evolving safety profile of Decoy20 during the expansion part of our Phase 1 trial. Our goal is to continue to evaluate patients receiving two distinct weekly doses of Decoy20 to identify potential monotherapy activity, and to accumulate sufficient safety data to initiate combination therapy next year. “We ultimately believe that Decoy20’s broad but transient activation of multiple cytokines and chemokines responsible for stimulating both innate and adaptive immune pathways in concert with other therapies will enhance tumor regression.” Dr. Roger Waltzman, Indaptus Chief Medical Officer. Dr. Waltzman is a board-certified medical oncologist whose career highlights include the roll of Chief Medical Officer of publicly traded company, Molecular Templates (2019-2023) and multiple senior drug development roles at Novartis Oncology (2007–2013), where he played a leading role in the development of imatinib, nilotinib, and ruxolitinib. From 2013 to 2016, Dr. Waltzman was the Full Development Head of Malaria Drug Development at Novartis. More recently, Dr. Waltzman was CMO at Rgenix (now Inspirna), where he supervised the development of immuno-oncology and metabolic inhibitor assets through Phase 1 a/b. Previously, he served as CSO at Jaguar Health and Napo Pharmaceuticals, where he led scientific aspects of development and commercialization of Mytesi® (crofelemer).

 

Jeffrey Meckler, CEO, Indaptus Therapuetics, Inc. (NASDAQ: INDP)

“The clinical trial is progressing as planned. Enrolling multiple patients at two different weekly doses should accelerate the progress of our trials. We look forward to providing more updates later in the year,” stated Jeffrey Meckler, Chief Executive Officer.J effrey Meckler brings more than 30 years of financial and healthcare leadership experience to the company. Most recently, Jeff was the CEO of Intec Pharma, and prior to that, CEO of Cocrystal Pharma, transforming it from a research company into a clinical and development company. Earlier in his career, Jeff was managing director of the Andra Group, a life sciences consulting firm, and acted as a director and interim CEO of Cypress Bioscience after its acquisition by Royalty Pharma. Jeff started his career at Pfizer, where he held a series of positions in manufacturing systems, market research, business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures. He has also served as a director of QLT, Inc., Cocrystal Pharma, ClearFarma USA, Kyalin Bioscience, and Alveolus, and currently serves as director of Travere Therapeutics, where he also previously served as Chairman. Jeff is the past President and continues to serve on the Board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. He holds a B.S. in industrial management, an M.S. in industrial administration from the Tepper School of Business at Carnegie Mellon University, and a J.D. from Fordham University’s School of Law.


A founder of the company, Dr. Michael Newman currently serves as our Chief Scientific Officer. Most recently, he was Founder and CEO of Decoy Biosystems, where he developed the technology that serves as the foundation of Indaptus. With more than 35 years of experience carrying out and managing oncology drug discovery through early development in academia and at pharmaceutical and biotechnology companies, Michael has also served as a consultant to ~35 companies, assisting with target identification and prioritization, management of R&D, fundraising, and in/out-licensing. His previous positions include faculty appointments in biochemistry at Brandeis University and the Roche Institute of Molecular Biology, Senior Associate Director of Oncology at Sandoz Pharmaceuticals (world-wide head of Cancer Biology), Executive Director of Oncology at Novartis Pharmaceuticals (Head of Cancer Biology in the U.S.), and senior management positions at several Biotechnology companies, where he also managed drug discovery programs in inflammation, diabetes, and infectious disease. Michael received a Bachelor’s degree in biology from the University of California at San Diego, a Ph.D. in cell and developmental biology from Harvard Medical School (National Science Foundation Pre-doctoral Fellow) and carried out post-doctoral research at Cornell University.



Learn more now

To learn more, please visit the Indaptus Therapeutics (NASDAQ: INDP) website: https://indaptusrx.com